SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study
Version 3 2024-06-17, 10:29Version 3 2024-06-17, 10:29
Version 2 2024-06-02, 13:14Version 2 2024-06-02, 13:14
Version 1 2014-11-04, 11:26Version 1 2014-11-04, 11:26
journal contribution
posted on 2024-06-17, 10:29authored byMR Pizzo de Castro, M Maes, RL Guembarovski, CB Ariza, EM Reiche, HO Vargas, MM Vargas, LG de Melo, Seetal DoddSeetal Dodd, Michael BerkMichael Berk, MA Watanabe, SO Nunes
The aim of this study was to determine if variable number of tandem repeats (VNTR) in the second intron (STin2) of the serotonin transporter (SLC6A4) gene was associated with tobacco use disorder, successful smoking cessation, or smoking characteristics. In this case-control study, patients with current tobacco use disorder, diagnosed according to DSM IV criteria (n = 185), and never-smokers, diagnosed according to CDC criteria (n = 175), were recruited and received 52 weeks of combined pharmacotherapy and cognitive therapy. Successful smoking cessation was defined as exhaled carbon monoxide < 6 ppm. SLC6A4 gene STin2 VNTR polymorphism was assessed using a Multiplex-PCR-based method. At baseline, participants were evaluated using the Fagerström Test for Nicotine Dependence (FTND) and the ASSIST scale.